Quanterix (QTRX) Scheduled to Post Quarterly Earnings on Tuesday

Quanterix (NASDAQ:QTRX) is set to announce its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Quanterix (NASDAQ:QTRX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The firm had revenue of $34.38 million during the quarter, compared to the consensus estimate of $34.19 million. Quanterix had a negative return on equity of 11.52% and a negative net margin of 30.71%. During the same quarter in the previous year, the firm earned ($0.16) EPS. On average, analysts expect Quanterix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Quanterix Stock Performance

Shares of Quanterix stock opened at $15.10 on Monday. The company has a 50-day simple moving average of $12.86 and a two-hundred day simple moving average of $14.03. The stock has a market capitalization of $579.54 million, a PE ratio of -14.38 and a beta of 1.36. Quanterix has a 52-week low of $10.50 and a 52-week high of $29.70.

Wall Street Analysts Forecast Growth

Several brokerages have commented on QTRX. Scotiabank cut their target price on Quanterix from $32.00 to $28.00 and set a “sector outperform” rating on the stock in a research note on Monday, August 12th. TD Cowen dropped their price objective on Quanterix from $17.00 to $15.00 and set a “hold” rating on the stock in a research report on Friday, August 9th.

Insiders Place Their Bets

In other news, Director David R. Walt purchased 47,000 shares of the stock in a transaction dated Tuesday, August 20th. The shares were purchased at an average cost of $13.29 per share, with a total value of $624,630.00. Following the acquisition, the director now directly owns 1,487,342 shares of the company’s stock, valued at $19,766,775.18. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 6.90% of the stock is currently owned by insiders.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.